Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized Controlled, Open-Label Study of Ripertamab Combined With Eltrombopag Versus Eltrombopag for ITP Patients After First-Line Steroid Therapy

NCT06790888 is registered in ClinicalTrials.gov with Union Hospital, Tongji Medical College, Huazhong University of Science and Technology as lead sponsor.

NCT NCT06790888
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06790888 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized Controlled, Open-Label Study of Ripertamab Combined With Eltrombopag Versus Eltrombopag for ITP Patients After First-Line Steroid Therapy
Lead sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase
Not applicable
Overall status
Not yet recruiting
Start date
February 28, 2025
Completion date
December 31, 2027
Enrollment
78 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

itp - immune thrombocytopenia